Oppenheimer Reiterates Outperform Rating on Boston Scientific Corporation (BSX)

Market Context

Boston Scientific Corporation operates in the Healthcare sector. The stock currently trades at $45.51 with a market capitalization of $136.0B. The stock has declined 56.9% over the past 52 weeks.

Analyst coverage from Oppenheimer provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Boston Scientific Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Boston Scientific Corporation

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 27, 2026	Oppenheimer	Outperform	N/A
Jul 16, 2026	Truist Securities	Buy	N/A
Jul 15, 2026	Mizuho	Outperform	N/A
Jul 13, 2026	RBC Capital	Outperform	N/A
Jul 08, 2026	Needham	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View BSX Stock Page